BCM
BLCM

BlueCrest Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

BlueCrest Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,145
Closed -$75K – 1922
2018
Q1 		$75K Buy
+1,145
New +$86.5K ﹤0.01% 1397
2017
Q2 		– Sell
-1,759
Closed -$217K – 1157
2017
Q1 		$217K Buy
+1,759
New +$230K 0.01% 604

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's BLCM Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 1,145 shares — an estimated $75K sold.

BlueCrest Capital Management first reported a position in BLCM in Q1 2017 and held it in 2 quarters. The position peaked at $217K in Q1 2017. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,145 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $75K.
  • BlueCrest Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $217K in Q1 2017.
  • 96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.